Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

A monoclonal antibody for terminal β-galactose. Use in analysis of glycosphingolipids

Abstract

A monoclonal antibody (mAb 8281) specific for the terminal β-galactose (βGal) of glycosphingolipids (GSL) and glycoproteins was produced from mice immunized with lipid extract from fresh acute lymphocytic leukemia (ALL) cells. Immuno-thin layer chromatography (ITLC) and competition assays with purified neutral GSL standards, free sugars, and synthetic neoglycoproteins showed mAb 8281 to be strongly reactive with LacCer, GalCer and Gal-β-O-(CH3)2S(CH3)2-CONH-(Gal-β-O-CETE) linked to bovine serum albumin (BSA). The penultimate sugar also played a role in binding. The antibody was not reactive with carbohydrates with terminal αGal structures and unrelated terminal moieties. Indirect immunoperoxidase staining and flow cytometry with mAb 8281 demonstrated positive staining on numerous tissues, including smooth muscle, gastrointestinal mucosa, lymph node B cells and monocytes. ITLC analysis of the GSL composition of fresh B cell neoplasms using mAb 8281 confirmed the presence of lactosylceramide and galactosylceramide in neoplasms of varying stages of differentiation. Because of its specificity for terminal βGal carbohydrate residues, mAb 8281 may be useful in structural and functional analyses of GSL.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Roos RH, Hartman HJ, Schlepper-Shaffer J, Kolb H, Kolb-Bachofen V (1985)Biochim Biophys Acta 847:115–21.

  2. 2.

    Kempa G, Kolb-Bachofen V (1985)Biochim Biophys Acta 847:108–14.

  3. 3.

    Clarke BL, Oka JA, Weigel PH (1987)J Biol Chem 262:17384–92.

  4. 4.

    Aziwa S, Tavassoli M (1988)Exp Hematol 16:811–13.

  5. 5.

    Lackie AM, Vasta GR (1988)Immunology 64:353–7.

  6. 6.

    Galili U, Rachmilewitz A, Peleg A, Flechner I (1984)J Exp Med 160:1519–31.

  7. 7.

    Galili U, Flechner I, Knyszynski A, Danon D, Rachmilewitz EA (1986)Br J Haematol 62:317–24.

  8. 8.

    Galili U, Korkesh A, Kakane I, Rachmilewitz EA (1983)Blood 61:1258–64.

  9. 9.

    Galili U, Shohet SB, Kobrin E, Stults CL, Macher BA (1988)J Biol Chem 263:17755–62.

  10. 10.

    Galili U, Macher BA, Buehler J, Shohet SB (1985)J Exp Med 162:573–82.

  11. 11.

    Castronovo V, Colon C, Parent B, Froidant JM, Lambotte R, Maniere P (1989)J Natl Cancer Inst 8:212–16.

  12. 12.

    Thurin J (1988) InCurrent Topics in Microbiology and Immunology, Vol 139, pp 59–79. Berlin: Springer-Verlag.

  13. 13.

    Hakomori S (1981)Ann Rev Biochem 50:733–64.

  14. 14.

    Hakomori S, Kannagi R (1983)J Natl Cancer Inst 71:231–51.

  15. 15.

    Yogeeswaran G, Salk B (1981)Science 212:1514–16.

  16. 16.

    Symington FW, Bernstein ID, Hakomori S (1984)J Biol Chem 259:6008–12.

  17. 17.

    Ito M, Suzuki E, Naiki M, Sendo F, Arai S (1984)Int J Cancer 34:689–97.

  18. 18.

    Hoggs N, Horton MA (1987) InLeukocyte Typing II (McMichael AJ, ed.) pp 576–602. New York: Oxford University Press.

  19. 19.

    Hakomori S (1983) InHandbook of Lipid Research (Hanahan DJ, ed.) pp 1–166. New York: Plenum Press.

  20. 20.

    Makita A, Taniguchi N (1985) InGlycolipids (Weigandt H, ed.) pp 1–99. New York: Elsevier Science Publishers.

  21. 21.

    Livingston PO, Natola EJ, Calves MJ, Stockert E, Oettgen HF, Old LJ (1987)Proc Natl Acad Sci USA 84:2911–15.

  22. 22.

    Kohler G, Milstein C (1975)Nature 256:495–7.

  23. 23.

    Schulman M, Wilde CD, Kohler G (1978)Nature 276:269–70.

  24. 24.

    Magnani JL, Brockhaus M, Smith DF, Ginsburg V (1982)Methods Enzymol 83:235–41.

  25. 25.

    Furukawa K, Clausen H, Hakomori S, Sakamoto J, Look K, Lundblad A, Mattes MJ, Lloyd KO (1985)Biochemistry 24:7820–6.

  26. 26.

    Suzuki Y, Suzuki K (1972)J Lipid Res 13:687–90.

  27. 27.

    Van Muiyen GNP, Ruiter DJ, Ponec M, Huiskens-van der Mey C, Wainaar SO (1984)Am J Pathol 114:9–17.

  28. 28.

    Scheinberg DA, Tanimoto M, McKenzie S, Strife A, Old LJ, Clarkson BD (1989)Leukemia 3:440–5.

  29. 29.

    Hunter WM (1986) InHandbook of Experimental Immunology (Weir DM, ed.) pp 608–42. Philadelphia: FA Davis Co.

  30. 30.

    Kalisiak A, Scheinberg DA, Minniti JG, Old LJ (1988)Blood 72:Suppl 1, 268a (Abstract).

  31. 31.

    Nakakuma H, Arai M, Kawaguchi T, Horikawa K, Hidaka M, Sakamoto K, Iwamori M, Nagai Y, Takatsuki K (1989)FEBS Lett 258:230–2.

  32. 32.

    Schrump DA, Furukawa K, Yamaguchi H, Lloyd KO, Old LJ (1988)Proc Natl Acad Sci USA 85:4441–5.

  33. 33.

    Gahmberg CG, Hakomori S (1973)J Biol Chem 248:4311–17.

  34. 34.

    Symington FW, Murray MA, Bearman SI, Hakomori S (1987)J Biol Chem 262:11356–63.

Download references

Author information

Correspondence to D. A. Scheinberg.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kalisiak, A., Oosterwijk, E., Minniti, J.G. et al. A monoclonal antibody for terminal β-galactose. Use in analysis of glycosphingolipids. Glycoconjugate J 8, 55–62 (1991). https://doi.org/10.1007/BF00731643

Download citation

Keywords

  • β-galactose
  • glycosphingolipids
  • monoclonal antibody